SCI & TECH● LOWSep 8 · Sep 8, 2026, 12:55 PM
Intellia rises on FDA priority review for one-time hereditary angioedema therapy
Seeking Alpha Tech · north america
Intellia's stock has risen after its one-time hereditary angioedema therapy received priority review from the FDA. This indicates a fast-tracked regulatory assessment for a potential new medical treatment.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Sci & Tech
SCI & TECH24m agoUkraine deposits seed samples in Svalbard Global Seed VaultUkrinform [en]SCI & TECH29m agoLeap second no longer of this time, international measurement authority abolishes itNOS BuitenlandSCI & TECH43m agoEU moves toward fast-track approval of Airbus, Leonardo, Thales satelliteSeeking Alpha TechSCI & TECH1h agoUkraine testing new 'evacuation drone' that rescues wounded soldiers from battlefieldThe Independent World